
Phreesia Inc (PHR) Stock Forecast & Price Target
Phreesia Inc (PHR) Analyst Ratings
Bulls say
Phreesia is well-positioned for future growth due to its integrated software and payments platform addressing healthcare delivery challenges, and its diverse customer base including ambulatory practices, health systems, and life sciences companies. This has been reflected in the company's strong adjusted EBITDA margin, expected to reach 28% by the end of FY27, and potential for upside risks to the current price target and rating. Furthermore, the company's recent acquisition of AccessOne may lead to additional growth opportunities, although it has seen a decline in revenue and net income in recent years. While there may be some challenges in integrating and scaling this business, Phreesia's track record of successful acquisitions suggests a positive outlook for the company's long-term growth prospects.
Bears say
Phreesia is facing headwinds in its Network Solutions segment due to weak pharmaceutical demand, and also has concerns about its ability to cross-sell into large health systems that use Epic as their primary EHR. Additionally, the healthcare industry is rapidly evolving and the market for technology-enabled services is immature and unproven, which could limit Phreesia's growth potential. The company also faces competition from both smaller, point solution vendors and larger, well-capitalized players, and may struggle to retain clients due to provider consolidation. Overall, there are significant fundamental risks for Phreesia that could hinder its long-term success.
This aggregate rating is based on analysts' research of Phreesia Inc and is not a guaranteed prediction by Public.com or investment advice.
Phreesia Inc (PHR) Analyst Forecast & Price Prediction
Start investing in Phreesia Inc (PHR)
Order type
Buy in
Order amount
Est. shares
0 shares